Better Responses Lead to Improved Outcomes in High-Risk Smoldering Myeloma
Author Information
Author(s): Nadeem Omar, Michelle P. Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D. Lightbody, Jean-Baptiste Alberge, Luca Bertamini, Ankit K. Dutta, Habib El-Khoury, Mark Bustoros, Jacob P. Laubach, Giada Bianchi, Elizabeth O’Donnell, Ting Wu, Junko Tsuji, Kenneth C. Anderson, Gad Getz, Lorenzo Trippa, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Irene M. Ghobrial
Primary Institution: Dana-Farber Cancer Institute
Hypothesis
Does the depth of response in high-risk smoldering multiple myeloma predict long-term outcomes?
Conclusion
The study found that deeper responses significantly improve time to progression in patients with high-risk smoldering multiple myeloma.
Supporting Evidence
- 93% overall response rate was observed in the trial.
- 31% of patients achieved complete response.
- 45% achieved very good partial response or better.
- MRD-negativity predicted a 5-year biochemical PFS of 100%.
Takeaway
If patients with high-risk smoldering myeloma have a better response to treatment, they are likely to do better in the long run.
Methodology
The I-PRISM phase II trial evaluated ixazomib, lenalidomide, and dexamethasone in 55 patients with high-risk smoldering multiple myeloma.
Potential Biases
Potential biases may arise from the single-arm design and lack of a control group.
Limitations
The study had a small sample size and was limited to a single-arm trial design.
Participant Demographics
{"median_age":64,"age_range":"40-84","male_percentage":55}
Statistical Information
P-Value
0.051
Confidence Interval
95% CI: 39.9–NR
Statistical Significance
p=0.051
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website